At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 137 enrolled
Drug / intervention
Cyclosporine Ophthalmic Emulsion 0.05% (RESTASIS®) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety and Efficacy Study of Cyclosporine Ophthalmic Emulsion in Post-LASIK Patients
In Brief
A Phase 2 clinical trial evaluating Cyclosporine Ophthalmic Emulsion 0.05% (RESTASIS®) and Artificial Tears REFRESH ENDURA® for Dry Eye Syndromes. Completed, enrolled 137 participants across 1 site.
Detailed Summary
This study will evaluate the safety and efficacy of cyclosporine ophthalmic emulsion administered twice daily following LASIK surgery
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDry Eye Syndromes
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartDec 2007
First PostedFeb 2008
Primary CompletionDec 2008
Study CompletionJun 2009
TodayJul 2026
First PostedFeb 8, 2008
Enrollment StartDec 1, 2007
Primary CompletionDec 1, 2008
Study CompletionJun 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 18.4 years ago
Interventions
Cyclosporine Ophthalmic Emulsion 0.05% (RESTASIS®)drug
Cyclosporine Ophthalmic Emulsion 0.05% administered twice daily in each eye for 6 months following LASIK surgery
Artificial Tears REFRESH ENDURA®drug
REFRESH ENDURA® administered twice daily in each eye for 6 months following LASIK surgery